AG真人官方

Be the most trusted biotech company

2025-09-30

U.S. FDA Clearance of IND for Ipilimumab Biosimilar HLX13
2025-09-30

Henlius Receives the NMPA IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-EGFR mAb HLX07
2025-09-28

Henlius Holds 2025 Scientific Advisory Board Meeting in Shanghai, Gathering Global Experts to Advance Frontier Innovations
2025-09-26

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Proposed Pembrolizumab Biosimilar
2025-09-24

Results of Serplulimab in Lung and Gastrointestinal Cancer Selected for ESMO 2025: Late-Breaking Abstract and Oral Presentations
2025-09-24

First Patient Dosed in Argentina for the Phase 3 Head-to-Head Trial of HLX22 in Gastric Cancer
2025-09-22

Henlius Participates in FDA Biosimilars Industry Roundtable
2025-09-19

European Commission (EC) Approves Henlius and Organon’s BILDYOS??(denosumab) and BILPREVDA??(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-09-19

First Patient Dosed in Australia for a Phase 2 International Clinical Trial of Henlius' PD-L1 ADC HLX43 for NSCLC

【网站地图】【sitemap】